Nycomed is planning to build a plant to manufacture active pharmaceutical ingredients (APIs) and has already finished dosage forms for the Russian pharmaceutical market as well as the Commonwealth of Independent States (CIS). The company has said that it would be among the first overseas manufacturers to produce APIs in Russia.
The company has claimed that it would invest E65 to E75m in the facility, which will be located near the city of Yaroslavl about 280 kms from Moscow, and is expected to start construction in 2010 and open in 2014.
Moreover, the liquid production area is reported to handle preparation, washing of ampoules, sterilisation, filling and inspection, while solid dose production will encompass all stages, from mixing and granulation through compression and coating. The unit will also have an integrated packaging line for both solid and liquid medicines.
Nycomed has said that it would make products such as Cardiomagnyl (acetylsalicylic acid and magnesium hydroxide) for pain relief, Actovegin (a deproteinised derivative of calf blood) and the anticoagulant warfarin.
Hakan Bjorklund, chief executive of Nycomed, said: “The investment underlines our belief in the long-term prospects of the pharmaceutical market in Russia-CIS, which was valued at more than $10billion last year, according to figures from Espicom.